-Reuters
Protagonist Therapeutics Offers Updated Data From Phase 2 Study Of Rusfertide In Polycythemia Vera Selected For Oral Presentations At American Society Of Hematology Dec. 11-12
Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control while essentially eliminating phlebotomy
Additional abstracts to be presented at ASH, providing further